Современная стратегия ведения пациентов с синдромом фолликулярной окклюзии
Синдром фолликулярной окклюзии представляет собой хроническое воспалительное заболевание кожи, включающее гнойный гидраденит, конглобатные акне, абсцедирующий и подрывающий фолликулит и перифолликулит Гоффмана, эпителиальный копчиковый ход. Заболевание имеет хроническое непрерывно-рецидивирующее течение и оказывает серьезное влияние на качество жизни пациента. Ранняя диагностика и лечение могут эффективно сдерживать прогрессирование заболевания, предотвращать формирование обезображивающих рубцов, уменьшать патологическое влияние заболевания на соматическое и психическое здоровье пациентов, а также снижать экономическое бремя. В настоящее время нет единого консенсуса относительно терапии синдрома фолликулярной окклюзии. В статье освещаются и обсуждаются существующие в мире подходы к терапии этой сложной категории пациентов.Боткина А.С., Гуменная Э.Р., Тюхаева О.Ю.
Ключевые слова
Список литературы
1. Zouboulis C.C., Bechara F.G., Fritz K., et al. S2k guideline for the treatment of hidradenitis suppurativa/acne inversa – Short version. J Dtsch Dermatol Ges. 2024;22(6):868–89. https://dx.doi.org/10.1111/ddg.15412
2. Federico A., Rossi A., Caro G., et al. Are dissecting cellulitis and hidradenitis suppurativa different diseases? Clin Dermatol. 2021;39(3):496–9. https://dx.doi.org/10.1016/j.clindermatol.2021.01.002
3. Pillsbury D.M., Shelley W.B. Dermatology. Annu Rev Med. 1954;5:363–88. https://dx.doi.org/10.1146/annurev.me.05.020154.002051
4. Plewig G., Kligman A.M. Acne. Morphogenesis and Treatment. Berlin: Springer. 1975. Р. 192–3.
5. Plewig G., Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, editors. Acne and Related Disorders. London: Martin Dunitz. 1989. Р. 345–57.
6. Sabat R., Jemec G.B.E., Matusia., et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. https://dx.doi.org/10.1038/s41572-020-0149-1
7. Sung K.Y., Lee S., Jeong Y., Lee S.Y. Dissecting cellulitis of the scalp: A diagnostic challenge. Arch Plast Surg. 2020;47(6):631–2. https://dx.doi.org/10.5999/aps.2020.00633
8. Gulliver W., Zouboulis C.C., Prens E., et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343–51. https://dx.doi.org/10.1007/s11154-016-9328-5
9. Chu Y.L., Yu S. Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment. Biomedicines. 2024;12(2):338. https://dx.doi.org/10.3390/biomedicines12020338
10. Frew J.W. Intrinsic factors in the pathogenesis of hidradenitis suppurativa: Genetics, hormones, and the microbiome. J Am Acad Dermatol. 2024;91(6S):S12–6. https://dx.doi.org/10.1016/j.jaad.2024.08.052
11. Nikolakis G., Kokolakis G., Kaleta K., et al. Pathogenese der Hidradenitis suppurativa/Acne inversa
12. Wang Z., Yan Y., Wang B. Secretase Genetics of Hidradenitis Suppurativa: A Systematic Literature Review. Dermatology. 2021;237(5):698–704. https://dx.doi.org/10.1159/000512455
13. Verma S.S., Sharma K., Chhabra S. Pathogenesis of Hidradenitis Suppurativa: An Immunological Perspective. Indian J Dermatol. 2023;68(3):296–300. https://dx.doi.org/10.4103/ijd.ijd_594_22
14. Jastrz B., Szepietowski J.C., Matusiak Ł. Hidradenitis suppurativa and follicular occlusion syndrome: Where is the pathogenetic link? Clin Dermatol. 2023;41(5):576–83. https://dx.doi.org/10.1016/j.clindermatol.2023.08.021
15. Frew J.W., Hawkes J.E., Krueger J.G. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646. https://dx.doi.org/10.1177/2040622319830646
16. Ceruti J.M., Leirs G.J., Balana M.E. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018;465:122–33. https://dx.doi.org/10.1016/j.mce.2017.09.009
17. Nikolakis G., Kyrgidis A., Zouboulis C.C. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol. 2019;20(4):503–13. https://dx.doi.org/10.1007/s40257-019-00442-w
18. Yook H.J., Kim E., Kim Y.H., et al. A link between smoking behaviors and the risk of hidradenitis suppurativa in diabetic patients. PLoS One. 2025;20(6):e0325357. https://dx.doi.org/10.1371/journal.pone.0325357
19. Ng-Wong Y.K., Alexander B., Bartl M., et al. Deeper Seated Than Skin Deep: Report of a Rare Case of Follicular Occlusion Tetrad and a Literature Review. Cureus. 2023;15(5):e39474. https://dx.doi.org/10.7759/cureus.39474
20. Tricarico P.M., Boniotto M., Genovese G., et al. An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis. Front Immunol. 2019 Apr 25;10:892. https://dx.doi.org/10.3389/fimmu.2019.00892
21. Liu T., Li S., Ying S., et al. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front Immunol. 2020;11:594735. https://dx.doi.org/10.3389/fimmu.2020.594735
22. Savage K.T., Flood K.S., Porter M.L., Kimball A.B. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:2040622319851640. https://dx.doi.org/10.1177/2040622319851640
23. Ingram J.R. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990–8. https://dx.doi.org/10.1111/bjd.19435
24. Хайрутдинов В.Р., Бурова С.А., Олисова О.Ю. и др. Гнойный гидраденит: обзор международных клинических рекомендаций по диагностике и лечению заболевания. Вестник дерматологии и венерологии. 2024;100(3):7–16.
25. Клинические рекомендации. Гидраденит гнойный. Год утверждения 2023.
26. Mahmood F., Hussain A., Akingboye A. Pilonidal sinus disease: Review of current practice and prospects for endoscopic treatment. Ann Med Surg (Lond). 2020;57:212–7. https://dx.doi.org/10.1016/j.amsu.2020.07.050
27. Magalhães R.F., Rivitti-Machado M.C., Duarte G.V., et al. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl. 1):7–19. https://dx.doi.org/10.1590/abd1806-4841.20198607
28. Alikhan A., Sayed C., Alavi A., et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101. https://dx.doi.org/10.1016/j.jaad.2019.02.068
29. Baran A., Kwiatkowska A., Potocki L. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race. Int J Mol Sci. 2023;24(6):5777. https://dx.doi.org/10.3390/ijms24065777
30. Goldburg S.R., Strober B.E., Payette M.J. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol. 2020;82(5):1061–82. https://dx.doi.org/10.1016/j.jaad.2019.08.089
31. Alshehri A.A., Althobaiti B.A., Khawagi W.Y., Murphy K.D. Awareness of isotretinoin use and safety in Saudi Arabia: A nationwide cross-sectional study. Saudi Pharm J. 2023;31(11):101796. https://dx.doi.org/10.1016/j.jsps.2023.101796
32. Zouboulis C.C., Bechara F.G., Dickinson-Blok J.L., et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31. https://dx.doi.org/10.1111/jdv.15233
33. Lucky A.W., Koltun W., Thiboutot D., et al. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008;82(2):143–50.
34. Riis P.T., Ring H.C., Themstrup L., Jemec G.B. The Role of Androgens and Estrogens in Hidradenitis Suppurativa - A Systematic Review. Acta Dermatovenerol Croat. 2016;24(4):239–49.
35. Hambly R., Kearney N., Hughes R., et al. Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators. Int J Mol Sci. 2023;24(8):6969. https://dx.doi.org/10.3390/ijms24086969
36. Petrasca A., Hambly R., Kearney N., et al. Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa, Br J Dermatol. 2023;189(6):730–40. https://doi.org/10.1093/bjd/ljad305
37. Hendricks A.J., Hsiao J.L., Lowes M.A., Shi V.Y. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81–96. https://dx.doi.org/10.1159/000503605
38. Alikhan A., Sayed C., Alavi A., et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90. https://dx.doi.org/10.1016/j.jaad.2019.02.067
39. Chawla S., Toale C., Мorris М., et al. Surgical management of hidradenitis suppurativa: a narrative review. J Clin Aesthet Dermatol. 2022;15(1):35–41.
40. Yeroushalmi S., Ildardashty A., Elhage K.G., et al. Hidradenitis suppurativa and sleep: a systematic review. Arch Dermatol Res. 2023;315(5):1409–15. https://dx.doi.org/10.1007/s00403-022-02460-x
41. Di Guida A., Forgione P., Fornaro L., et al. Step by step surgery for hidradenitis suppurativa. Dermatol Ther. 2022;35(12):e15938. https://dx.doi.org/10.1111/dth.15938
42. Guermazi D., Shah A., Yumeen S., Saliba E. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review. Arch Dermatol Res. 2024;316(6):259. https://dx.doi.org/10.1007/s00403-024-03121-x
43. Zouboulis C.C., Okun M.M., Prens E.P., et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–9.e2. https://dx.doi.org/10.1016/j.jaad.2018.05.040
44. Zouboulis C.C., Bechara F.G., Dickinson-Blok J.L., et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31. https://dx.doi.org/10.1111/jdv.15233
45. Schettini N., Marzola E., Pacetti L., et al. Case of Dissecting Cellulitis of the Scalp, Hidradenitis Suppurativa, and Conglobate Acne Successfully Treated with Secukinumab. Skin Appendage Disord. 2024;10(3):232–5. https://dx.doi.org/10.1159/000537914
46. Snyder C.L., Gibson R.S., Porter M.L., Kimball A.B. Secukinumab in the treatment of hidradenitis suppurativa. Immunotherapy. 2023;15(17):1449–57. https://dx.doi.org/10.2217/imt-2023-0103
47. Stergianou D., Kanni T., Damoulari C., et al. arellos-Bourboulis E.J. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa. Expert Opin Biol Ther. 2024;24(4):225–32. https://dx.doi.org/10.1080/14712598.2024.2343112
48. Lipa K., Zajac N., Witkowski G., et al. Hidradenitis suppurativa – biologic therapy and other available treatment options. Postepy Dermatol Alergol. 2023;40(4):518–28. https://dx.doi.org/10.5114/ada.2021.112075
49. Hendricks A.J., Hsiao J.L., Lowes M.A., Shi V.Y. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81–96. https://dx.doi.org/10.1159/000503605
50. Hurley H.J. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: Surgical approach. In: Dermatologic Surgery: Principles and Practice, Roenigk R.K., Roenigk H.H. (Eds), Marcel Dekker. 1989. 729 p.
51. Prens L.M., Rondags A., Volkering R.J., et al. The refined Hurley classification: the inter-rater and intrarater reliability and face validity. Br J Dermatol. 2019;181(6):1335–7. https://dx.doi.org/10.1111/bjd.18235
Об авторах / Для корреспонденции
Александра Сергеевна Боткина, к.м.н., доцент кафедры госпитальной педиатрии им. акад. В.А. Таболина педиатрического факультета, Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва, Россия; botkina@gmail.com, ORCID: https://orcid.org/0000-0001-6890-2041 (автор, ответственный за переписку)Э.Р. Гуменная, Российская детская клиническая больница – филиал ФГАОУ ВО РНИМУ им. Н.И. Пирогова, Москва, Россия; ORCID:
https://orcid.org/0000-0002-8097-2816
О.Ю. Тюхаева, Российская детская клиническая больница – филиал ФГАОУ ВО РНИМУ им. Н.И. Пирогова, Москва, Россия; ORCID:
https://orcid.org/0009-0009-2656-3278